Liraglutide

FDA-approved product existsMetabolic ResearchWeight & metabolic
5.2

Neutral, BioHarmony verdict

BioHarmony score 5.2 out of 10

Liraglutide is a once-daily prescription GLP-1 receptor agonist. In the 3,731-person SCALE trial, 3.0 mg with lifestyle counseling produced 8.4 kg mean weight loss versus 2.8 kg on placebo over 56 weeks, and in LEADER it lowered major cardiovascular events in high-risk type 2 diabetes (HR 0.87). A 2025 Cochrane review rated most obesity outcomes low to moderate certainty.

Read full report

What is Liraglutide?

Liraglutide is a once-daily injectable GLP-1 receptor agonist, prescribed for type 2 diabetes and, at a higher dose, for chronic weight management in adults and in adolescents 12 and older who weigh more than 60 kg and have obesity. It was the first GLP-1 drug with a positive cardiovascular outcome trial. In the 56-week SCALE trial, 3,731 adults on liraglutide 3.0 mg plus lifestyle counseling lost 8.4 kg on average versus 2.8 kg on placebo (Pi-Sunyer 2015). An independent Cochrane review later confirmed that liraglutide raises the likelihood of meaningful weight loss, while rating several other obesity outcomes low or very low certainty.

From the BioHarmony report, reviewed Oct 13, 2026.

Saved on this device only.

How it is thought to work

GLP-1 receptor agonism: glucose-dependent insulin release, glucagon suppression, slower gastric emptying, lower appetite

Safety watch-outs

  • Severe upper abdominal pain radiating to the back, with or without vomiting: stop and seek urgent care for a pancreatitis check.
  • Personal or family history of medullary thyroid carcinoma or MEN 2: liraglutide is contraindicated.
  • A neck lump, hoarseness or trouble swallowing: get it evaluated.
  • Shakiness, sweating or confusion while also using insulin or a sulfonylurea: treat low blood sugar and have doses reviewed.
  • Persistent vomiting or diarrhea with signs of dehydration: seek care, since dehydration can injure the kidneys.

Full risk profile in the BioHarmony report.

Dosing as published

Source-reported figures only. This page does not calculate a personal dose.

Approved labelSAXENDA prescribing information for chronic weight management
PopulationAdults and adolescents covered by the approved SAXENDA indication
Dose0.6 mg daily in week 1, 1.2 mg in week 2, 1.8 mg in week 3, 2.4 mg in week 4, and 3 mg from week 5 onward. The label provides separate pediatric tolerability instructions.
RouteSubcutaneous injection in the abdomen, thigh, or upper arm
FrequencyOnce daily
DurationLong-term use within the approved indication; initial escalation spans 5 weeks
PreparationReady-to-use 6 mg/mL solution in a 3 mL prefilled pen; no reconstitution.
Source: Dosage and Administration sections 2.1-2.2; Dosage Forms and Strengths section 3

Working with a vial? The reconstitution calculator covers mixing math, not dosing advice.

More reported protocols

Members

Members can compare additional reported doses, schedules, and preparation notes.

Educator coverage (1)

Attributed viewpoints, separate from primary research.

Trust & sourcing

  1. Last revieweddone
  2. Next reviewupcoming
US approvalFDA-approved product exists
CompoundingFDA has proposed excluding liraglutide from the 503B bulks list after finding no clinical need

FDA-approved liraglutide products exist, including Saxenda for chronic weight management and Victoza for type 2 diabetes.

Primary sources

The Ultimate Peptides Guide

Spot stronger candidates, weak evidence, and seller red flags before you buy.

Free. Includes evidence and regulatory updates. Unsubscribe anytime.